Introduction
Atrial fibrillation (AF) is the most common clinical arrhythmia with an estimated lifetime risk of one in four after 40 years of age. 1 Atrial fibrillation is associated with a two-fold increase in mortality with stroke being the most devastating complication. The risk of AF-related stroke rises from 1.5% annually in the 6th decade to 24%
annually in the 9th decade. 2 Overall, non-valvular AF is associated with five-fold greater risk of stroke even after adjusting for other stroke risk factors. 2 Only anticoagulation has been demonstrated to reduce AF-related mortality. Recently, asymptomatic AF has been detected in patients with cardiac implantable electronic devices (CIEDs) and termed as 'subclinical' or 'device-detected AF'. At present, the significance of asymptomatic short episodes of subclinical AF and the strategy for anticoagulation, in this scenario, is not well defined. In addition, there is gap in knowledge on the temporal relationship of the AF episode and stroke in this population. Therefore, we performed a systematic review and meta-analysis to evaluate the prevalence of subclinical AF, association with stroke risk, and temporal association with stroke.
Methods
This systematic review complied with the consensus statement outlined by the Meta-analysis of Observational Studies in Epidemiology group. 3 
Search strategy
The English scientific literature was searched using Pubmed and Embase with keywords ('subclinical' OR 'device-detected') AND atrial fibrillation' AND ('pacemaker' OR Implantable Cardioverter Defibrillator OR Cardiac Resynchronization Therapy Device OR CIED) up to 1 April 2016 with the assistance of an experienced librarian. The retrieved references were exported to EndNote X7.3 and duplicate citations removed. Two independent investigators (R.M. and T.P.) assessed the resulting citations.
Inclusion and exclusion criteria
The articles of interest were those describing the association of devicedetected subclinical AF and stroke in patients with CIEDs with implanted atrial leads. The exclusion criteria were: (i) intermittent monitoring for AF detection; (ii) conference abstracts, editorials, reviews, letters, and case reports; (iii) reviews were excluded but their reference lists hand searched for potential relevant publications; (iv) case series with less than 50 patients.
Where multiple studies described the same population (substudies, followup studies), the study with the most comprehensive data was included.
Study selection and data extraction
The study selection and data extraction were performed by the authors (R.M. and T.P.), using a priori determined criteria. During data extraction, information was collected on the study design, follow-up time, outcome measures, method of assessing outcomes, inclusion/exclusion criteria, and results. The data were collected by one review author and independently checked by the second author. Disagreements were resolved by consensus. The methodological qualities of the included studies were assessed using the modified Newcastle-Ottawa Scale.
The outcomes of the analysis were defined as: (i) definition of subclinical AF in different studies and cutoff for recognizing subclinical AF; (ii) prevalence of subclinical AF; (iii) association of subclinical and clinical AF; (iv) association of subclinical AF and stroke risk; and (v) temporal relationship of subclinical AF and stroke in patients with CIEDs.
Statistical analysis
Continuous variables are presented as the mean or median, and categorical variables as n (%). Separate meta-analyses were performed for: (i) association of subclinical AF and clinical AF; (ii) stroke risk in subclinical AF; and (iii) temporal association of stroke and subclinical AF. The temporal association between subclinical AF and stroke was performed after excluding patients without subclinical AF (persistent sinus rhythm). Where meta-analysis was not feasible due to small patient or study numbers, raw results were tabulated. The I 2 statistic and heterogeneity P-value were used as a measure of variability in observed effect estimates attributable to heterogeneity between the studies. For the meta-analysis of odds ratios, the Dersimionian and Laird inverse variance randomeffects model was used using Review Manager Version 5.3 (Nordic Cochrane Center, Copenhagen, Denmark). To compute pooled stroke incidence rates, data on the number of thrombo-embolic events and follow-up (person-years) was extracted from each study cohort.
A Poisson-Normal model with log incidence rate as the outcome measure was fitted, using the restricted maximum-likelihood estimator random effects model. Back-transformation of log incidence rates was then performed to compute the pooled incidence rate. Meta-analysis of incidence rates was performed using R Version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria).
Results

Search and synthesis of the literature
The online search of Pubmed and EMbase upto 1 April 2016 yielded 2227 citations. Hand searching of references of reviews did not yield additional citations. Of these, 2143 citations were excluded as they did not meet the inclusion criteria. Eighty-four citations were identified for secondary review. After removal of case series, reviews, redundant, and non-relevant articles, 11 studies were for inclusion into the final analysis. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Of these seven studies (15 353 patients) reported prevalence of subclinical AF, two studies (2892 patients) reported association between subclinical and clinical AF, seven studies (15 353 patients) reported stroke risk in subclinical AF, and five studies (8551 patients, 181 strokes) reported temporal relationship of subclinical AF and stroke. Two additional sub-studies evaluated temporal relationship of subclinical AF and stroke. Figure 1 provides an overview of the data search.
Definition and cut-off for detection of subclinical atrial fibrillation
Clinical AF was defined as electrocardiogram documented AF. Subclinical AF was defined as device-detected atrial high rate episodes (AHRE). There was variability in the programming and detection algorithm used by the CIEDs utilized in the different studies. However, all studies (i) laid down certain criteria for defining AHRE, (ii) then utilized a minimum cut-off time for recognizing subclinical AF (to improve specificity) and (iii) finally analysed different durations of subclinical AF for stroke risk. For example, the TRENDS study (Medtronic pacemakers) used an atrial amplitude sensitivity of 0.5 mV and defined AHRE as atrial rate more than 175 b.p.m. and lasting at least 20 s. 5 A daily cumulative burden was calculated by adding all the episodes occurring in a day. They finally used the highest cumulative daily subclinical AF burden in a rolling window of 30 days for evaluating association with stroke. Figure 2 provides a summary of definition and cut-off points for detection of subclinical AF. Baseline characteristics and prevalence of subclinical atrial fibrillation
The baseline characteristics of the patients are given in the Supplementary material online, Table S1 . Table 1 ). Overall, subclinical AF was noted after CIEDs implant in 35% [interquartile range (IQR) 34-42] of all patients within a follow-up period of 1-2.5 years. In the ASSERT study, where previous AF was an exclusion criterion, subclinical AF was detected in 13.9% new patients annually.
Association between subclinical and clinical atrial fibrillation
Two studies, consisting of 2892 patients, reported on the association of subclinical and clinical AF. ASSERT excluded patients with previous AF. Ancillary MOSTT enrolled patients with sinus node disease who were in sinus rhythm at the time of pacemaker implant. 38% of patients in the Ancillary MOSTT had prior history of supraventricular arrhythmias and were not excluded from analysis. Patients with documented subclinical AF were 5.7 times (95% CI 4.0-8.0, P < 0.001) more likely to have documented clinical AF during the follow-up period. The data were homogeneous across the studies (I 2 = 0%, P = 0.88 for heterogeneity). Figure 3A shows the forest plot demonstrating association of subclinical and clinical AF.
Subclinical atrial fibrillation and stroke risk
Seven studies with a total of 15 353 patients reported on the association between subclinical AF and stroke and demonstrated a significant association. The duration of subclinical AF that was associated with stroke risk varied in different studies. For example, >6 min in ASSERT and >5.5 h in TRENDS (see Table 1 ). Subclinical AF was associated with a 2.4-fold increased risk of stroke (95% CI 1.8-3.3, P < 0.001; I 2 = 0%, P = 0.69 for heterogeneity). The absolute annual stroke risk with and without subclinical AF was 1.89 (95% CI 1.02-3.52) and 0.93 (95% CI 0.58-1.49) per 100 person-years, respectively. Three studies provided the overall CHADS 2 score of the patient population with a score of 2.1 ± 0.1. Importantly, in these studies with a mean CHADS 2 score = 2.1, the absolute annual stroke with and without subclinical AF was 2.76 (95% CI 1.46-5.23) and 1.08 (95% CI 0.55-2.12) per 100 person-years, respectively. Figure 3B shows the forest plot demonstrating the association of subclinical AF and stroke risk.
Temporal association of subclinical atrial fibrillation and stroke risk
Five studies, consisting of 8551 patients and 181 strokes during the period of observation, reported on the temporal association between subclinical AF and stroke ( Table 2 ). The patients with stroke consisted of a mix population of patients with subclinical AF and those who never had subclinical AF. Of the overall 181 strokes that occurred in five studies, 83 strokes occurred in patients who were never documented to have subclinical AF. Only 98 strokes occurred in patients who had subclinical AF during the follow-up period. Among these latter 98 patients, 17% of strokes were occurred during an episode of subclinical AF. Only TRENDS and ASSERT studies provided data on the proportion of patients with subclinical AF in the preceding 30 days of the index stroke.
Of the strokes that were preceded by subclinical AF, 55% (11/20) and 22% (4/18) strokes were noted to have subclinical AF in the preceding Table 2) . Adjudication of ischaemic stroke to cardioembolic or non-cardioembolic was not performed in any study. Furthermore, anticoagulation was on physician discretion and not adjusted for in analyses ( Table 2) .
Study quality
All studies reporting association of subclinical AF and stroke represented a device-detected subclinical AF population and had an adequate sample size. Three of seven studies attempted adjustment for CHADS 2 score or anticoagulation, and all studies reported these parameters without adjusting. There was low risk of detection and information biases in all studies. The modified Newcastle Ottawa score for these studies is shown in the Supplementary material online, Table S2 .
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In contrast, the analysis of temporal association had several biases in all five studies. The source population was not representative, and all had a mix of patients with and without AF. Adjudication of strokes to cardioembolic or non-cardioembolic and adjustment for anticoagulation was not performed in any studies (performance biases). 
Discussion
Device-detected subclinical AF is increasingly recognized and expands the horizons of the true burden of AF in the community. However, there is limited consensus on the clinical implications and prognosis of such a finding. This systematic review and meta-analysis provides the following information based on the currently available literature:
(1) Subclinical AF is highly prevalent in patients with CIEDs and predicts clinical AF. (2) Subclinical AF was associated with a 2.4-fold increase in stroke risk.
However, the overall absolute annual risk of stroke was 1.89 per 100 person-years. For studies that provided CHADS 2 score, the absolute annual stroke risk is higher at 2.76 per 100 person-years for a mean CHADS 2 score of 2. 
Accuracy and pitfall of atrial fibrillation detection by cardiac implantable electronic devices
Cardiac implantable electronic devices provide a unique opportunity for continuous monitoring. However, AF detection algorithms have their own limitations. The CIEDs may over-sense and falsely interpret AF due to far field R-wave detected on atrial channel or due to pacemaker mediated arrhythmias. 5, 14 Cardiac implantable electronic devices may under-detect AF due to under-sensing of the atrial electrogram or incorrectly log a long episode as multiple short episodes. The positive predictive value for AF detection has been shown to be 95.3% and 91% for Medtronic 17 and Biotronik CIEDs, respectively.
10
St Jude CIEDs have been shown to have a positive predictive value of 96.7% for AHRE episodes >6 h. However, it declined to 82.7% for episodes >6 min to 6 h. 14 Despite the limitations, the predictive value for true AF is high for longer episodes of device-detected AF and manual adjudication may be essential for short episodes.
Subclinical atrial fibrillation/AHRE predicts clinical atrial fibrillation
Subclinical AF is noted in one third of patients with CIEDs within the first few years after device implant. Subclinical AF was associated with an almost six-fold risk of clinical AF. This may reflect diagnosis of AF in early stages due to continuous monitoring with CIEDs in patients. In addition, a proportion of patients with AF are asymptomatic and remain undiagnosed until detection by the implanted CIEDs.
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Cut-off point for predicting stroke risk in subclinical atrial fibrillation
The cut-off point for predicting stroke risk in subclinical AF varied between studies from 6 min episodes (ASSERT) to 1 h (SOS AF) to >5.5 h daily burden (TRENDS). However, the risk is uniformly increased (I 2 = 0). Nevertheless, on stratification according to duration of AF, the stroke risk was only elevated when median episode length exceeded 17 h in ASSERT. 7 Similarly, increased stroke risk was counter-intuitively noted with >1 h of burden but not with >6, 12 and 23 h of burden in the SOS AF study. 9 Therefore, we hypothesize that elevated stroke risk in patients with >6 min episode in ASSERT and >1 h of daily burden in SOS AF may be have been driven by longer episodes. Capucci et al. 13 and Botto et al. 6 showed association of 24-h episode with stroke risk. Furthermore, data from Finnish Cardioversion study indicate higher stroke risk for AF duration >12 h, particularly in certain subsets such as heart failure. 19, 20 Nevertheless, another important piece of information gleamed from this meta-analysis is that short subclinical AF episodes (<described cut-off) are associated with a very low stroke risk that may not to warrant anticoagulation. This is consistent with a recent study confirming absence of increased stroke risk with short episodes (15-20ses) of adjudicated AF. 21 
Stroke risk in subclinical atrial fibrillation and its determinants
Although the stroke risk with subclinical AF is lower compared to historical stroke risk defining cohorts, 22 it is similar to contemporary AF cohorts. 23 A lower stroke risk in the subclinical AF studies as compared to historical clinical AF cohorts may be explained by a lesser AF burden, 24 lower CHADS 2 score of study population, 6, 7 and discretionary anticoagulation of some patients with subclinical AF. Subclinical AF related thrombo-embolic risk has also been shown to be stratified based on CHADS 2 score (four-fold for CHADS 2 score > 2 in ASSERT) with and presence/duration of AF. 6 The current meta-analysis had three studies that provided the mean CHADS 2 score. The mean CHADS 2 score in these studies was 2.1 with an annual stroke risk of 2.76 per 100 person-years. This is lower than 4 per 100 person-years risk (similar CHADS 2 score) in the original NRAF cohort described by Gage et al., 22 but similar to 2.58
per 100 person-years risk reported in the ATRIA study cohort (Take home figure) . 23 The reduced risk of stroke in subclinical cohorts may represent smaller AF burdens and could potentially be attributed to aggressive treatment of risk factors.
24-28
Temporal relationship of subclinical atrial fibrillation and stroke
All studies reporting on the temporal association of subclinical AF and stroke demonstrated temporal dissociation. these studies suffered from three biases that may have tempered this conclusion. First, the temporal association was assessed in a mixed cohort of patients with and without subclinical AF rather than restricting the analysis to patients with documented subclinical AF. Nearly half of all strokes occurred in patients who never had subclinical AF and were included in the analysis of the individual studies. Second, there was no adjudication to cardioembolic and non-cardioembolic stroke in all studies. The pathogenesis of stroke is multifactorial in high-risk patients with AF. 29 Atherosclerotic plaques in ascending and transverse aorta are frequently reported in high-risk patients with AF and are potential source of non-cardioembolic ischaemic stroke. 29 The available literature suggests that cardio-embolism represents only 73% of classifiable ischaemic strokes in patients with AF. 30 Finally, a sizable proportion received anticoagulation at physician discretion in all studies included in the current meta-analysis. Ischaemic strokes in anticoagulated AF patients are more likely to be non-cardioembolic. 30 Anticoagulation has been demonstrated to reduce the proportion of cardioembolic stroke from 66% to 16% in patients with clinical AF. 31 The SPAF III substudy has demonstrated a similar reversal of proportion of cardioembolic to non-cardioembolic ischaemic strokes with anticoagulation in patients with clinical AF. 30 The current meta-analysis excluded patients with stroke who never had documented subclinical AF. Despite this exclusion, only 17% of strokes occurred during an episode of AF. Furthermore, 29% of all strokes in patients with subclinical AF had AHRE in the preceding 30 days of stroke. The lack of adjudication (proportion of strokes noncardioembolic) and discretionary anticoagulation (ischaemic strokes more likely to be non-cardioembolic) could potentially account for the temporal dissociation noted in several studies. A recent casecrossover analysis has also confirmed acute increase in risk of ischaemic stroke with device-detected AF in a large cohort of patients with CIEDs. 32 This risk was transient, dissipating weeks after the end of the AF episode.
Limitations
The meta-analysis was performed utilizing observational studies that demonstrated different AF duration cut-off for elevated stroke risk and does not attempt to provide a single cut-off for AF duration/burden for stroke risk. Furthermore, there is a potential for publication bias as were unable to assess this specifically due to limited study numbers. Nevertheless, the meta-analysis shows homogeneity of the elevated stroke risk with subclinical AF and allows calculation of absolute stroke risk in patients with subclinical AF. The risk of stroke could be underestimated due to the anticoagulation at physician discretion.
Conclusion
Subclinical AF is frequent in patients with CIEDs and is strongly associated with clinical AF. The stroke risk with subclinical AF is low as compared to clinical AF and could potentially represent smaller burden. Further research is required to define the role of AF burden in stroke risk.
Supplementary material
Supplementary material is available at European Heart Journal online. Take home figure Demonstrates the incidence and positive predictive value of atrial high rates episodes, association with clinical AF and duration of AHRE associated with elevated stroke risk. It also shows the comparison of stroke risk in subclinical atrial fibrillation to original hospitalized NRAF cohort and more contemporary ATRIA cohort. The absolute stroke risk in subclinical atrial fibrillation (CHADS 2 score = 2) is well-above accepted current threshold of 1% for anticoagulation for stroke prevention (dotted line).
